 HAYWARD, Calif., June 1, 2021 PRNewswire -- AcelRx Pharmaceuticals, Inc. Nasdaq: ACRX, AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced important findings from a podium presentation on DSUVIA sufentanil sublingual tablet 30 mcg during the Best Papers of the Regional Societies session at the California Society of Plastic Surgeons 71st Annual Meeting in Monterey CA. 